Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose University of Galway as their University of choice. Find out what life at University of Galway is all about here.
About University of Galway
About University of Galway
Since 1845, University of Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
University of Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
- Research & Innovation
Business & Industry
Guiding Breakthrough Research at University of Galway
We explore and facilitate commercial opportunities for the research community at University of Galway, as well as facilitating industry partnership.
- Alumni & Friends
At University of Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
November 2017 NUI Galway Publishes Findings from Studies on Treating the Progression of Aggressive Breast Cancer
NUI Galway Publishes Findings from Studies on Treating the Progression of Aggressive Breast Cancer
New research from the Discipline of Pathology at NUI Galway’s Lambe Institute for Translational Research led by Dr Sharon Glynn, has identified that a protein in the body called inducible nitric oxide synthase or iNOS is a key cause for the aggressive spread of triple negative breast cancer, which results in increased risk of early death from the disease. Almost 30% of women in the Western world are diagnosed with this form of breast cancer, which currently cannot be treated or stopped with therapies such as tamoxifen and is limited to treatment through chemotherapy and surgery. These findings will lead to new research to determine what drives this aggressive form of the disease and to develop new therapies and improve survival.
Triple negative breast cancer, the most aggressive form of breast cancer is frequently diagnosed in younger women ranging from their thirties and upwards. Based on this research Dr Glynn’s laboratory has had two landmark papers published in the international journals, Proceedings of the National Academy of Sciences and Oncotarget, which investigates the role of iNOS and the protein COX2 in this type of breast cancer. iNOS and COX2 are normally activated when the body experiences inflammation and wound healing. Dr Glynn’s research shows that when both proteins are expressed together in triple negative breast cancer, they lead to faster tumour growth and help the tumour to spread around the body.
In the first study, published in Oncotarget, Dr Glynn and her NUI Galway colleagues Dr Pablo Garrido, Dr Aideen Ryan and Professor Grace Callagy found that women with increased expression of iNOS were at greater risk of their breast cancer spreading to other parts of their body, leading to poor survival rates. They conducted a study of 206 women across the Western seaboard diagnosed with breast cancer at Galway University Hospital between 2000 and 2016, and found that iNOS was a factor in the poor survival rate of Irish breast cancer patients with triple negative breast cancer. It made the cells more resistant to treatment such as chemotherapy, aiding in tumour cell growth and a much higher risk of the disease spreading, leading to death.
Speaking about the research, Dr Sharon Glynn at NUI Galway, said: “The results from both studies will be used to develop screening methods to identify which patients are at increased risk of developing the lethal disease. The team are also focused on developing new therapeutic drugs that shut down both of these proteins and reduce the spread of cancer which can lead to premature death in the future. Both proteins have been identified as key drivers in the spreading or metastasis of triple negative breast cancer, and targeting them may save the lives of these patients.”
The second study, published in Proceedings of the National Academy of Sciences was edited by the Nobel Laureate, Dr Louis Ignarro, a world expert in nitric oxide biology. Dr Glynn collaborated with Dr Debashree Basudhar and Dr David Wink at the National Cancer Institute in the US and demonstrated for the first time that patients who express high levels of iNOS in conjunction with high levels of the protein COX2, are at an increased risk of tumour progression throughout the body and high risk of death. The study was carried out with patients from Maryland in the US. It found that five years post-diagnosis, less than 40% of women with high levels of iNOS and COX2 survive, compared to 95% of women with low levels of both proteins.
To read the full study in Proceedings of the National Academy of Sciences, visit: http://www.pnas.org/content/early/2017/10/26/1709119114.full
To read the full study in Oncotarget, visit: www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5b%5d=19631&path%5b%5d=62719